ArticleHealth policy and planning2026
Cost-effectiveness analysis of vitamin A supplementation delivery modalities in the DRC, Togo, and Niger: informing sustainable program design.
Article in Health policy and planning, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study examines how the costs, health impacts, and efficiency of two-dose vitamin A supplementation (VAS) vary across delivery platforms, population subgroups, and delivery contexts in Togo, Niger, and the Democratic Republic of the Congo (DRC). Using a scenario-based model, it compares provider costs and disability-adjusted life years (DALYs) averted and identifies reallocations that maximize health gains under fixed budget constraints. Costs were estimated from the health provider perspective, and health outcomes were measured in DALYs averted. The results showed that cost-effective scenarios varied significantly across countries; in the DRC and Niger, campaigns delivered high coverage but at a substantially higher cost than routine delivery, whereas in Togo, campaigns were both low-cost and high-coverage. In all countries, the most cost-effective scenarios prioritized children aged 6-23 months. More than two-thirds of the cost-effective scenarios achieved better outcomes at lower cost than countries' current delivery strategies, highlighting significant potential for efficiency gains. A positive, nonlinear relationship between incremental costs and DALYs averted was observed: greater investment generally led to larger health gains but returns diminished as costs increased. A sensitivity analysis showed that facility-based supply shortages negatively affected effectiveness, whereas strengthened routine delivery improved effectiveness. Optimal VAS strategies must be context-specific, balancing the reach of campaigns with the sustainability of routine services. The decision tool provides a practical mechanism for identifying cost-effective delivery strategies tailored to national capacities and constraints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.